Belvedere Trading’s Anavex Life Sciences AVXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-11,000
Closed -$39.2K 755
2025
Q4
$39.2K Buy
+11,000
New +$67.4K ﹤0.01% 676
2025
Q1
Sell
-23,000
Closed -$247K 704
2024
Q4
$247K Hold
23,000
﹤0.01% 373
2024
Q3
$131K Sell
23,000
-1,000
-4% -$5.77K ﹤0.01% 425
2024
Q2
$101K Hold
24,000
﹤0.01% 439
2024
Q1
$122K Sell
24,000
-2,300
-9% -$12.9K ﹤0.01% 403
2023
Q4
$245K Sell
26,300
-1,800
-6% -$12.4K ﹤0.01% 293
2023
Q3
$184K Buy
28,100
+1,400
+5% +$11.1K ﹤0.01% 233
2023
Q2
$217K Buy
+26,700
New +$229K ﹤0.01% 296
2023
Q1
Sell
-20,200
Closed -$187K 938
2022
Q4
$187K Buy
+20,200
New +$216K ﹤0.01% 357

Other funds holding AVXL

Belvedere Trading's AVXL Position: Q4 2022 in Review

Belvedere Trading sold out of Anavex Life Sciences (AVXL) in Q4 2022, closing a stake of 582 shares — an estimated $6.22K sold.

Belvedere Trading first reported a position in AVXL in Q3 2022 and held it in 1 quarter. The position peaked at $7K in Q3 2022. 139 funds tracked by Wall St. Rank hold AVXL as of Q4 2022.

  • Belvedere Trading reported no remaining Anavex Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Belvedere Trading sold 582 Anavex Life Sciences shares in Q4 2022, an estimated $6.22K.
  • Belvedere Trading first reported a position in Anavex Life Sciences in Q3 2022 and held it in 1 quarter.
  • Belvedere Trading's Anavex Life Sciences position peaked at $7K in Q3 2022.
  • 139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2022.

Based on Belvedere Trading's 13F filing for Q4 2022, filed 15 Feb 2023.